Provided by Tiger Trade Technology Pte. Ltd.

HENGRUI PHARMA

48.440
-0.700-1.42%
Volume:7.71M
Turnover:381.01M
Market Cap:321.50B
PE:35.06
High:51.000
Open:49.740
Low:48.280
Close:49.140
52wk High:90.435
52wk Low:43.020
Shares:6.64B
HK Float Shares:258.00M
Volume Ratio:1.56
T/O Rate:2.99%
Dividend:0.23
Dividend Rate:0.48%
EPS(LYR):1.381
ROE:12.46%
ROA:7.02%
PB:4.26
PE(LYR):35.06
PS:8.77

Loading ...

Mingyu Pharma, Led by Hengrui Veteran, Files for Hong Kong IPO Amid Fierce Market Competition

Deep News
·
Jul 15

Movement Alert|Hengrui Medicine Falls 3.05% in Regular Trading, FDA Issues Third Complete Response Letter for PD-1 Combination Therapy

Market Focus
·
Jul 14

Hengrui Pharmaceuticals Gets China Nod For Lupus, Arthritis Drug Trials

MT Newswires Live
·
Jul 14

Hengrui Pharma's HRS-7058 Capsule Designated as Breakthrough Therapy

Stock News
·
Jul 13

Hengrui Pharma's FXI Antibody SHR-2004 Unveils Pivotal Phase III Data at ISTH 2026 LBA Session

Deep News
·
Jul 13

AH Share Premium and Deviation Rankings as of July 13th Close

Stock News
·
Jul 13

Hengrui Pharma's Key Drug Iohexol Injection Added to National Essential Medicines List

Stock News
·
Jul 10

AH Share Premium and Deviation Rankings for July 10

Stock News
·
Jul 10

Hengrui Pharma Receives FDA Complete Response Letter for Camrelizumab Injection Application

Stock News
·
Jul 10

Movement Alert|Hengrui Pharma Rises 3.08% in Regular Trading, UBS Reiterates Buy Rating on Positive Weight-Loss Drug Data

Market Focus
·
Jul 10

UBS Reiterates 'Buy' on Hengrui Pharma, Citing Positive Weight-Loss Drug Data and Attractive Valuation

Stock News
·
Jul 09

AH Share Premium and Deviation Data for July 8th

Stock News
·
Jul 08

Movement Alert|Hengrui Medicine Rises 3.6% in Regular Trading, Proprietary Anti-Tumor Drug SHR-4685 Approved for Clinical Trials

Market Focus
·
Jul 08

Are "Old Economy" Stocks Signaling a Market Shift?

Deep News
·
Jul 06

AH Share Premium and Deviation Data for July 6th

Stock News
·
Jul 06

Movement Alert|Hengrui Pharma Rises 4.01% in Regular Trading, Pharmaceutical Sector Rallies Amid Multiple Drug Approval Catalysts

Market Focus
·
Jul 06

AH Share Premium and Deviation Rankings for July 3rd

Stock News
·
Jul 03

Movement Alert|Hengrui Pharma Rises 3.2% in Regular Trading, Multiple New Drug Approvals and Priority Review Catalyze Gains

Market Focus
·
Jul 03

Hengrui Pharma Gets Nod to Trial Drug Combination for Hepatocellular Carcinoma

MT Newswires Live
·
Jul 03

Hengrui Pharma Reports Cumulative Share Buyback Totaling 13.47 Million A-Shares as of June 30

Stock News
·
Jul 02